Zai Lab
ZLABZLAB · Stock Price
Historical price data
Overview
Zai Lab is a patient-focused, global biopharma founded in 2014 with a mission to bridge scientific innovation from the West with deep market access and development capabilities in Greater China. The company has established itself as a fully integrated organization with eight commercialized products in China and a promising pipeline of internally discovered and in-licensed assets. Its core strategy combines a hybrid business model of strategic partnerships and internal R&D to address significant unmet medical needs across its core therapeutic areas.
Technology Platform
An Integrated Global Operational Platform combining fully integrated end-to-end biopharma capabilities with a hybrid business model of strategic partnerships and internal R&D, designed to bridge Western innovation with development and commercial execution in Greater China.
Pipeline
36| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ZL-1310 + Investigator's Choice of Therapy | Small-cell Lung Cancer | Phase 3 | |
| Omadacycline + Moxifloxacin | Community-acquired Bacterial Pneumonia | Phase 3 | |
| ZL-2306 (Nirapairb) + Placebo Comparator | Ovarian Cancer | Phase 3 | |
| ZL-2306(nirapairb) + Placebo | Extensive-stage Small Cell Lung Cancer | Phase 3 | |
| Xanomeline and Trospium Chloride Capsules + Placebo | Schizophrenia | Phase 3 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Competes with large domestic Chinese pharma and other global-minded biotechs like BeiGene in China, and with global biopharma on its internal pipeline. Its differentiation lies in its fully integrated, West-East operational platform and proven track record as a partner.
Company Timeline
Founded in Shanghai and Cambridge, China
Series B: $100.0M
IPO — $173.0M
Follow-on Offering: $750.0M